Cheryl A. Pugh

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.

Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.

Journal: Lancet (London, England)

Published: October 05, 2023

Enhancing involvement of people with multiple sclerosis in clinical trial design.

Enhancing involvement of people with multiple sclerosis in clinical trial design.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: August 09, 2023

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.

Journal: The Lancet. Oncology

Published: January 23, 2023

Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).

Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).

Journal: International journal of cancer

Published: December 10, 2021

Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial.

Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: November 10, 2021

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.

Journal: Lancet (London, England)

Published: October 12, 2021

This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols.

This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols.

Journal: Trials

Published: August 10, 2018

Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial.

Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial.

Journal: Lancet (London, England)

Published: September 09, 2016

Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial.

Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial.

Journal: Journal of clinical pathology

Published: April 23, 2015

Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial.

Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial.

Journal: The Lancet. Oncology

Published: April 08, 2014

Showing 1-10 of 10

Last Updated: 09/26/2026